Among patients with mildly reduced or heart failure and preserved ejection fraction (HFpEF) both SGLT2 inhibitors and more recently, steroidal mineralocorticoid receptor antagonists (MRAs) have been shown to reduce the rate of hospitalization for heart failure.26 Here, SLC5A2 is linked to heart failure.